Unlearn, an 8VC investment, has developed the first machine learning platform for creating Intelligent Control Arms with Digital Twins, allowing drug developers to dramatically improve clinical evidence and trial power, while lowering the risk of trial failure, thereby increasing confidence in clinical trial results. Unlearn works with biopharmaceutical and medical device companies as well as regulators to ensure its methods meet the highest scientific and regulatory standards.
Occam placed Sana Hafeez as the company’s first Head of People in 2022. Prior to Unlearn, Sana was an HR leader holding positions of increasing responsibility at entrepreneurial Tech and Biotech companies including, TopHatter, Qventus and ImagoBioSciences. Sana began her career as a research scientist at Stanford University and holds a Bachelor’s in Science in Cell Biology from the University of Michigan.